Previous studies have demonstrated that the increased expression of YAP1 or its analog TAZ significantly diminishes the sensitivity of the lung adenocarcinoma cell line carrying the BRAF V600E mutation (HCC364) to vemurafenib and trametinib. The gene discussed is BRAF; the disease is lung adenocarcinoma.